Literature DB >> 20134008

Travel and travelers' diarrhea in patients with irritable bowel syndrome.

Herbert L DuPont1, Greg Galler, Francisco Garcia-Torres, Andrew W Dupont, Anthony Greisinger, Zhi-Dong Jiang.   

Abstract

This study evaluated occurrence of travel and travelers' diarrhea in patients with irritable bowel syndrome (IBS). A survey was mailed to 591 patients of a clinical practice who had IBS. Based on survey responses, patients were categorized as having IBS, post-infectious IBS (PI-IBS), unclassified functional bowel disorder (UFBD), or post-infectious UFBD (PI-UFBD). Of 201 persons who returned questionnaires meeting inclusion criteria, 57.7%, 11.4%, 24.9%, and 6.0% had IBS, UFBD, PI-IBS, and PI-UFBD, respectively. Travel during six months before illness onset was more common in patients with PI-IBS or PI-UFBD than in persons with idiopathic IBS or UFBD (P = 0.006). Survey results demonstrated that 16.1% of post-infectious bowel disorder cases and 7.5% of overall IBS cases in a general medical population developed chronic disease within six months of an international trip. Symptoms of established functional bowel disorder in each clinical category were shown to worsen after travel-related acute diarrhea.

Entities:  

Mesh:

Year:  2010        PMID: 20134008      PMCID: PMC2813172          DOI: 10.4269/ajtmh.2010.09-0538

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

Review 1.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

Review 2.  Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome.

Authors:  Bradley A Connor
Journal:  Clin Infect Dis       Date:  2005-12-01       Impact factor: 9.079

3.  Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study.

Authors:  Edy Stermer; Anat Lubezky; Israel Potasman; Eran Paster; Alexandra Lavy
Journal:  Clin Infect Dis       Date:  2006-08-25       Impact factor: 9.079

4.  Health-related quality of life among persons with irritable bowel syndrome: a systematic review.

Authors:  H B El-Serag; K Olden; D Bjorkman
Journal:  Aliment Pharmacol Ther       Date:  2002-06       Impact factor: 8.171

5.  A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea.

Authors:  David N Taylor; A Louis Bourgeois; Charles D Ericsson; Robert Steffen; Zhi-Dong Jiang; Jane Halpern; Robert Haake; Herbert L Dupont
Journal:  Am J Trop Med Hyg       Date:  2006-06       Impact factor: 2.345

6.  Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.

Authors:  D L Patrick; D A Drossman; I O Frederick; J DiCesare; K L Puder
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

Review 7.  Post-infectious irritable bowel syndrome.

Authors:  Andrew W Dupont
Journal:  Curr Gastroenterol Rep       Date:  2007-10

8.  Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico.

Authors:  Pablo C Okhuysen; Zhi Dong Jiang; Lily Carlin; Charles Forbes; Herbert L DuPont
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

9.  Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults.

Authors:  Hans Törnblom; Pia Holmvall; Bo Svenungsson; Greger Lindberg
Journal:  Clin Gastroenterol Hepatol       Date:  2007-04       Impact factor: 11.382

10.  Determinants of quality of life in irritable bowel syndrome.

Authors:  Enrique Rey; Monica Olga García-Alonso; Marta Moreno-Ortega; Angel Alvarez-Sanchez; Manuel Diaz-Rubio
Journal:  J Clin Gastroenterol       Date:  2008-10       Impact factor: 3.062

View more
  13 in total

1.  Deployment-associated functional gastrointestinal disorders: do we know the etiology?

Authors:  Ashok K Tuteja
Journal:  Dig Dis Sci       Date:  2011-11       Impact factor: 3.199

2.  Risk of functional gastrointestinal disorders in U.S. military following self-reported diarrhea and vomiting during deployment.

Authors:  Chad K Porter; Kayleen Gloor; Brooks D Cash; Mark S Riddle
Journal:  Dig Dis Sci       Date:  2011-06-04       Impact factor: 3.199

3.  Rifaximin for the treatment of acute infectious diarrhea.

Authors:  Kyoung Sup Hong; Joo Sung Kim
Journal:  Therap Adv Gastroenterol       Date:  2011-07       Impact factor: 4.409

4.  New Developments in Traveler's Diarrhea.

Authors:  Javier de la Cabada Bauche; Herbert L Dupont
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

5.  Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas.

Authors:  Adam Deising; Ramiro L Gutierrez; Chad K Porter; Mark S Riddle
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-03

6.  Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome.

Authors:  Chad K Porter; Brooks D Cash; Mark Pimentel; Akintunde Akinseye; Mark S Riddle
Journal:  BMC Gastroenterol       Date:  2012-05-28       Impact factor: 3.067

7.  Inconvenience due to travelers' diarrhea: a prospective follow-up study.

Authors:  Darius Soonawala; Jessica A Vlot; Leo G Visser
Journal:  BMC Infect Dis       Date:  2011-11-20       Impact factor: 3.090

8.  Predictors of aetiology and outcomes of acute gastrointestinal illness in returning travellers: a retrospective cohort analysis.

Authors:  Louis Tapper; Sophie Skarbek; Robert A Lever; Peter L Chiodini; Margaret Armstrong; Robin L Bailey
Journal:  BMC Infect Dis       Date:  2021-06-23       Impact factor: 3.090

9.  The gut microbiota and irritable bowel syndrome: friend or foe?

Authors:  Uday C Ghoshal; Ratnakar Shukla; Ujjala Ghoshal; Kok-Ann Gwee; Siew C Ng; Eamonn M M Quigley
Journal:  Int J Inflam       Date:  2012-04-22

10.  Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome.

Authors:  Charles Darkoh; Latoya Comer; Getie Zewdie; Stephen Harold; Ned Snyder; Herbert L Dupont
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.